检验医学与临床2017，Vol.14Issue(23)：3492-3494,3.DOI:10.3969/j.issn.1672-9455.2017.23.024
重组人血管内皮抑制素靶向治疗联合DP化疗在晚期非小细胞肺癌患者中的效果研究
Effect of recombinant human endostatin targeting therapy combined with DP chemotherapy on advanced non-small cell lung cancer
李兴 1马丽娜 2王美清 1崔荣龙1
作者信息
- 1. 中南大学湘雅医学院附属海口医院/海南省海口市人民医院肿瘤化疗科 570208
- 2. 中南大学湘雅医学院附属海口医院/海南省海口市人民医院神经内科 570208
- 折叠
摘要
Abstract
Objective To evaluate the curative effect of recombinant human endostatin targeting therapy combined with DP chemotherapy on advanced non-small cell lung cancer.Methods Sixty-eight cases of patients with advanced non-small cell lung cancer were selected and divided into experimental group and control group by the parity method.The control group were treated with DP chemotherapy,while the experimental group were treated with targeted therapy of recombinant human endostatin based on the control group.The clinical treatment effect,indexes of CT perfusion imaging,survival rates after 6 months,12 months,24months of following up and adverse reactions were compared between the two groups.Results The difference in the clinical treatment effect was statistically significant between the two groups(P＜0.05),and the total remission rate in the experimental group was significantly higher than that in the control group(P＜0.05).The blood flow(BF),blood volume(BV) and permeability surface (PS) levels in the experimental group were significantly lower than those in the control group,while the mean transit time(MTT) level was higher than that in the control group,and the differences in the indexes between the two groups were statistical signifi cance(P＜0.05).Progression free survival and a year cumulative survival rates in the experimental group were significantly higher than those in the control group(P＜0.05).The differences in the incidence rates and grade distribution of adverse reactions between the two groups were not statistically significant(P＞0.05).Conclusion Targeted therapy of recombinant human endostatin combined with DP chemotherapy in advanced non-small cell lung cancer could effectively improve the short-term effect and long term survival rate,which is worthy of promotion and application.关键词
重组人血管内皮抑制素/靶向治疗/DP化疗/非小细胞肺癌/CT灌注成像Key words
recombinant human endostatin/targeted therapy/DP chemotherapy/non-small cell lung cancer/CT perfusion imaging引用本文复制引用
李兴,马丽娜,王美清,崔荣龙..重组人血管内皮抑制素靶向治疗联合DP化疗在晚期非小细胞肺癌患者中的效果研究[J].检验医学与临床,2017,14(23):3492-3494,3.
